- 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
- 89Zr-girentuximab PET in Urothelial Cancer Patients
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma
- A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 )
- A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- A Multicenter Cancer Biospecimen Collection Study
- A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
- A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
- A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
- A PHASE 1/2 STUDY OF BA3071
- A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
- A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
- A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
- A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
- A PHASE II MULTICENTER STUDY OF CHEMOTHERAPY VERSUS CHEMOTHERAPY PLUS DURVALUMAB (MEDI 4736) IN PATIENTS WITH LYMPH NODE POSITIVE UROTHELIAL CARCINOMA OF THE BLADDER
- A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
- A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
- A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)
- A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up
- A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
- A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
- A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
- A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP Study)
- A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients
- A Study Evaluating MM-310 in Patients With Solid Tumors
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
- A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors
- A Study of a Personalized Neoantigen Cancer Vaccine
- A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
- A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
- A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
- A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
- A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
- A Study of CDX-585 in Patients With Advanced Malignancies
- A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
- A Study of ICP-192 in Patients With Advanced Solid Tumors
- A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
- A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
- A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
- A Study of Personalized Neoantigen Cancer Vaccines
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
- A Study of RC48-ADC Combined With Triplizumab For First-line Treatment of Urothelial Carcinoma
- A Study of RC48-ADC in Patients With HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma
- A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
- A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
- A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
- A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors
- A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
- A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
- A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
- A Study of ZN-c3 in Participants With Solid Tumors
- A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma
- A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
- A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)
- A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations
- A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
- A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
- A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
- A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
- A Study to Learn About First-line Avelumab Maintenance in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
- A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
- Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
- ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder
- Alisertib in Chemotherapy-pretreated Urothelial Cancer
- An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
- An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
- An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
- Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
- Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
- APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
- Application of UCAD for Diagnosing Urothelial Carcinoma.
- Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
- Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan
- ARON-2 Study-Multicentric International Retrospective Study
- Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma
- Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
- Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
- B-Receptor Signaling in Cardiomyopathy
- BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
- Bio Clinical Collection of Urothelial Carcinoma
- Biological Effect of Vitamin D in Patients With Urothelial Carcinoma
- Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
- Bladder Cancer Screening Trial
- Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
- Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
- Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
- Cabozantinib for Advanced Urothelial Cancer
- Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.
- Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
- CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors
- Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer
- Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
- CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma
- Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
- Confocal Laser Endomicroscopy in the Lower Urinary Tract
- Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
- CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
- Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
- Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
- Derazantinib and Atezolizumab in Patients With Urothelial Cancer
- Detecting Transitional Cell Carcinoma From Haematuria
- Development of Diagnostics and Treatment of Urological Cancers
- Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma
- Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
- DNA Methylation and Arsenic-associated Urothelial Carcinoma
- DNA Methylation and Urothelial Carcinoma
- Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications
- Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial
- Efficacy and Safety of UGN-101 in Recurrent Patients
- Efficacy and Utility of Cxbladder Tests in Hematuria Patients
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
- EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells
- En Bloc TURBT With Collins Loop vs Conventional TURBT
- Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
- Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
- Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction
- Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
- Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas
- Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study
- Expressing Personalized Tumor Antigens Study
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
- Fear of Cancer Recurrence in Genitourinary Cancer
- Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
- Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
- First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
- First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
- First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
- Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
- FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
- Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
- GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
- GEN1046 Safety Trial in Patients With Malignant Solid Tumors
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
- Glycosylation of Exosomes in Prostate and Urothelial Carcinoma
- Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
- Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
- Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Intravesical Adoptive Cell Therapy w/ TIL for BCG Unresponsive High Grade NMIBC
- Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT
- Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma
- Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:
- IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
- JAVLOR® Online Non-Interventional Trial
- KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
- KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
- LITT and Pembrolizumab in Recurrent Brain Metastasis
- Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
- Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer
- MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
- Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy
- Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
- Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
- Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
- MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer
- MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
- Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
- Named Patient Program for Mitomycin for Pyelocalyceal Solution
- Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
- Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
- Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
- Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
- Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
- Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
- Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
- Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
- Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
- Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma
- Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression
- NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers
- Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
- Patient-reported Outcomes in Bladder Cancer
- Pembrolizumab in MIBC
- Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
- Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma
- Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy
- PF-03446962 in Relapsed or Refractory Urothelial Cancer
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
- Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
- Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
- Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
- Phase I BLASST-3 Trial
- Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
- Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
- Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
- Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
- Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
- Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
- Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
- Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
- Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
- Predictive Factorsfor Final Pathologic Ureteral Sections
- Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
- Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
- Prospective Multicentric Evaluation of a Bladder Preservation Strategy
- Prospective Trial for Examining Hematuria Using Computed Tomography
- PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas
- Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
- Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
- Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
- Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
- Registry Platform Urologic Cancer
- Relationship of Ochratoxin A to Upper Urologic Cancers
- Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
- Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
- RTX-224 Monotherapy in Patients With Solid Tumors
- Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
- Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
- Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors
- Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
- Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
- Single Agent Abraxane as Second Line Therapy in Bladder Cancer
- SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
- Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
- Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
- Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
- Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
- Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
- Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
- Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
- Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
- Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection
- Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
- Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer
- Study of Sitravatinib and Nivolumab in Urothelial Carcinoma
- Study of the CD40 Agonistic Monoclonal Antibody APX005M
- Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
- Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
- Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
- Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
- Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
- Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
- Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
- The Cxbladder Hematuria Clinical Utility Study
- The Cxbladder Monitoring Study
- The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
- The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
- The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
- The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence
- The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer
- TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
- Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
- Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel
- Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
- Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
- Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
- Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
- Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy
- Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
- Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
- Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
- UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.
- Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic
- Urothelial Tumor Risk Genes Detection With Genetron Uro V1
- Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
- Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
- Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population
- Vasculogenic Mimicry in Urothelial Carcinoma
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
- Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
- Water Versus Saline as Irrigation Fluid for Ureteroscopy
- Weekly TP-HDFL in the Treatment of Advanced TCC
- Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Clinical Trials
- A Retrospective Comparison of the Efficacy and Safety of Celsior® in Pediatric Cardiac Surgery for Transposition of the Great Vessels
- Acute Maternal Hyperoxygenation for Fetal Transposition of the Great Arteries (TGA)
- Canadian Adult Congenital Heart Disease Intervention Registry
- Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT
- Cardiovascular Magnetic Resonance in Adults With SysTemic Right Ventricle (STAR)
- Cardiovascular MRI and Cardiopulmonary Exercise Capacity After Neonatal ASO) in Young Adults
- Characterization of the Cardiac Reinnervation of Patients With Transposition of the Great Arteries Long After Repair With the Arterial Switch Operation. Correlation With Electrocardiographic and Exercise Test Parameters
- Clinical Impact of Rapid Prototyping 3D Models for Surgical Management
- Comparison of Hematocrit Levels in Infant Heart Surgery
- Comprehensive Long-term Follow up of Adults With Arterial Switch Operation
- Eplerenone in Systemic Right Ventricle
- Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
- Fibrosis, Valvular and Ventricular Function in Patients With TGA
- Genetic Determinants of Congenital Heart Disease Outcomes
- Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance
- Influence of Timing of Switch Operation in Transposition of Great Arteries
- Initiation of Resuscitation While Attached to the Cord With Congenital Heart Disease
- Late Function After Surgery for Transposition of the Great Arteries
- MASA Valve Early Feasibility Study
- MRI Study After Arterial Switch Operation in Patients With Transposition of the Great Arteries
- Myocardial Contrast Echocardiography in Congenital Heart Disease
- N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
- Nitric Oxide During Bypass for Arterial Switch Operation
- Outcomes of Transposition of the Great Arteries After Arterial Switch Operation
- Physical Training in Transposition of the Great Arteries
- Sudden Cardiac Death in Systemic Right Ventricle
- The Boston Circulatory Arrest Study: Antecedents and Correlates of Well-Being in Adults With Congenital Heart Disease
- Biobank For MS And Other Demyelinating Diseases
- Central Pain Study for ABX-1431
- Clinical Trial of a Serious Game for Individuals With SCI/D
- Home Based Tele-exercise for People With Chronic Neurological Impairments: COVID and Beyond
- Injured Spinal Cord Pressure Evaluation Study – Transverse Myelitis
- Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
- PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
- Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
- Serum Auto-Antibodies in Neurological Diseases
- Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
- Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
- The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
- Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance
- A Study in Patients With Trichotillomania
- Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
- Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder)
- Cognitive Behavioral Therapy for Trichotillomania
- Cognitive Behavioral Treatment of Pediatric Trichotillomania
- Cognitive Training in Patients With Trichotillomania (Hair-pulling Disorder)
- Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania
- Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania
- Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors
- Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania
- Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions
- Evaluation of a Brief Surf the Urge Intervention
- Examining Behavior Therapy for Trichotillomania in Children and Adolescents
- Feasibility Study for Treating Trichotillomania With Wearable Device and App System
- Habit Reversal Training for Children and Adolescents With Trichotillomania
- Inositol in Trichotillomania
- Internet CBT for Trichotillomania and Skin Picking Disorder
- Leveraging Technological Advancements to Improve the Treatment of Trichotillomania
- Marinol in Trichotillomania or Obsessive Compulsive Disorder
- Methylphenidate in ADHD With Trichotillomania
- Milk Thistle in Trichotillomania in Children and Adults
- N-Acetyl Cysteine in Trichotillomania
- N-Acetylcysteine for Pediatric Trichotillomania
- Naltrexone in the Treatment of Trichotillomania
- Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
- Online Response Inhibition Training for Trichotillomania
- Online Treatment of Trichotillomania
- Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
- Response Inhibition Training for Individuals With Trichotillomania
- Stepped Care in the Treatment of Trichotillomania
- Technology Assisted Treatment for Trichotillomania
- Telepsychotherapy for the Treatment of Adolescents With Trichotillomania
- Testing a New Therapy for Trichotillomania
- Trial of Aripiprazole in Trichotillomania
- Trichotillomania: Group Cognitive-Behavioral Therapy
- Biomarker Study for Heart Failure in Children With Single Ventricle Physiology
- Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques
- Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients
- Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure
- Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease
- NIRS in Congenital Heart Defects – Correlation With Echocardiography
- Sildenafil After the Fontan Operation
- Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.
- Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
- Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery
- Assessment of Patients With Multiple Sclerosis (MS)
- Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis – Human T-Lymphotropic Virus 1 Infection
- Evaluation of Patients With HAM/TSP
- MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
- Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
- Urological Physical Therapy in HTLV-1 With Urinary Symptoms
- Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
- A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
- Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
- Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis
- Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF
- Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
- Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis
- Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis
- Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
- Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
- Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM
- Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis
- Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
- Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation
- Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone
- The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
- Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
- Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
- Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital
- A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
- A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
- Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
- Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
- An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
- Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
- Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
- Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
- Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France
- Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
- Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
- Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
- Doxycycline In Lymphangioleiomyomatosis (LAM)
- Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
- Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)
- Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
- Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
- Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
- Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
- Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
- Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
- Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
- Everolimus for Cancer With TSC1 or TSC2 Mutation
- Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex
- Gait in Rare Diseases
- Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom)
- JASPER Early Intervention for Tuberous Sclerosis
- KidneYou – Innovative Digital Therapy
- Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
- Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
- Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex
- Lymphangioleiomyomatosis, a Study on Cathepsin K
- Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy (TrustTSC OLE)
- Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
- Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
- Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
- RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
- Rapalogues for Autism Phenotype in TSC: A Feasibility Study
- Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
- Safety of Simvastatin in LAM and TSC
- Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
- Studies in Patients With Tuberous Sclerosis Complex
- Studies of Autistic Patients: Gene Networks and Clinical Subtypes
- Study of Skin Tumors in Tuberous Sclerosis
- Study of the Disease Process of Lymphangioleiomyomatosis
- The Cognitive Variability in NF1 and TSC Monozygotic Twins
- The Effectiveness and Safety of Resective Epilepsy Surgery for TRE
- The Effectiveness and Safety of Vagus Nerve Stimulation for TRE
- Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
- Topical Rapamycin to Erase Angiofibromas in TSC
- Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
- Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
- Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
- Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
- TSC Biosample Repository and Natural History Database
- Tuberous Sclerosis Complex Natural History Study: Renal Manifestations
- Turmeric as Treatment in Epilepsy
- Austrian Registry on the Outcome of Monochorionic Pregnancies
- Automated Myocardial Performance Index Using Samsung HERA W10
- Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.
- Continous Renal Replacement Therapy With the CARPEDIEM® in a French National Cohort of 25 Neonates and Small Infants
- Database of Monochorionic Pregnancies
- Emergency Cerclage in Twin Pregnancies at Imminent Risk of Preterm Birth: an Open-Label Randomised Controlled Trial
- Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
- Fetoscopic Selective Laser Photocoagulation in Twin-Twin Transfusion Syndrome
- Laser Photocoagulation in Twin to Twin Transfusion Syndrome
- Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome
- Neonatal Outcome for Laser Coagulation in Twin-to-twin-transfusion Syndrome
- Renal Artery Dopplers in Twin Twin Transfusion Syndrome
- Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome
- Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome
- The Utility of MRI Scoring to Predict Neurodevelopmental Outcomes in Survivors of Twin-to-Twin Transfusion Syndrome
- Virtual Reality Mask During in Utero Surgical Procedures
- Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
- Co-administration Study of OCV, TCV and MR
- Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
- Commercial Typhoid Tests Validation
- Commercial Typhoid Tests Validation Trial
- Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
- CVD 909 Vi Prime Boost Study
- Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
- Effectiveness of a Typhoid Conjugate Vaccine in DRC
- Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
- Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
- Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana
- Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
- Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
- Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
- Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
- Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
- Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
- Induction of Gut Permeability by an Oral Vaccine
- Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
- Investigating Enteric Fever – Salmonella Typhi and Paratyphi Challenge Study
- Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
- Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
- Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine ‘Typhocon’ in Bangladesh
- Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
- Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
- Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
- Safety and Immunogenicity of Typhax, a Typhoid Vaccine
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
- Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
- Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
- Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine
- Studies of Immune Responses to Orally Administered Vaccines in Developing Country
- Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
- The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
- Transcriptomic Responses for the Identification of Pathogens
- Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India
- Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
- Typhoid Fever: Combined vs. Single Antibiotic Therapy
- Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
- TyVECO: Surveillance Protocol
- Understanding Typhoid Disease After Vaccination
- Vaccines Against Salmonella Typhi
- Vellore Typhoid Vaccine Impact Trial
- WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study